Psychedelic drug developer Gilgamesh Pharmaceuticals has scooped a grant worth $14m from the National Institute on Drug Abuse (NIDA) to develop its ibogaine analog, GM-3009, for opioid use disorder (OUD). The company hopes that the compound will prove to be ‘cardiac-safe’, alluding to concerns around ibogaine’s cardiotoxicity which may represent a barrier to achieving FDA approval for the drug.

Here, we speak to Gilgamesh’s Co-Founder and Chief Scientific Officer, Andrew Kruegel, about the news.

This content is for Pα+ Subscribers

This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.